Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...

Researchers at Peking University have discovered that a filamentous gut fungus, Fusarium foetens, can reverse metabolic ...

AMSTERDAM — A once daily, 50 mg dose of efruxifermin reduced fibrosis at 96 weeks in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) compared with ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...

Target RWE, a leader in modern clinical evidence generation for complex diseases, today announced its presentations and strategic contributions at the EASL Congress 2025 in Amsterdam, Netherlands.

Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment landscape for patients with metabolic dysfunction-associated steatohepatitis ...

For decades, the search for effective treatments for metabolic dysfunction-associated steatohepatitis (MASH) — a form of fatty liver disease — has been marked by disappointment. Despite the ...

"It provides patients with additional choices when we think about treating fatty liver disease." MASH is a severe form of metabolic dysfunction-associated steatotic liver disease (MASLD), which ...